Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan

Journal of Rheumatology

Volumn 41, Issue 4, 2014, Pages 759-767

  Yokota, Shumpei ^a   Imagawa, Tomoyuki ^a   Mori, Masaaki ^b   Miyamae, Takako ^a   Takei, Syuji ^c   Iwata, Naomi ^d   Umebayashi, Hiroaki ^e   Murata, Takuji ^f   Miyoshi, Mari ^g   Tomiita, Minako ^h   Nishimoto, Norihiro ⁱ   Kishimoto, Tadamitsu ^j  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

^e MIYAGI CHILDREN S HOSPITAL   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g KOBE CHILDREN S HOSPITAL   (Japan)

^h CHIBA UNIVERSITY   (Japan)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j OSAKA UNIVERSITY   (Japan)

more..

Author keywords

Disease modifying antirheumatic drug; Interleukin 6 antagonists and inhibitors; Juvenile idiopathic arthritis; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CORTICOSTEROID; LACTATE DEHYDROGENASE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; TOCILIZUMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; BRONCHITIS; CELLULITIS; CHICKENPOX; CHILD; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ENTERITIS; FEMALE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HEAT RASH; HEPATITIS B; HERPES VIRUS INFECTION; HORDEOLUM; HUMAN; INFANT; INFECTION; INFLUENZA; INFUSION RELATED REACTION; JAPAN; JUVENILE RHEUMATOID ARTHRITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OTITIS MEDIA; PATIENT ASSESSMENT; PERITONSILLAR ABSCESS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SKIN ABSCESS; STOMATITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; URTICARIA; VOMITING; ARTHRITIS, JUVENILE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; RECEPTORS, INTERLEUKIN-6; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897451027     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130690     Document Type: Article

References (23)

1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
2. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther 2013;13:361-76.
3. Southwood TR, Foster HE, Davidson JE, Hyrick KL, Cotter CB, Wedderburn LR, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
4. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.
5. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48:1093-101.
6. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
7. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic idiopathic arthritis. N Engl J Med 2012;367:2396-406.
8. Pascual V, Allantaz R, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
9. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
10. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7: R1281-8.
11. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
12. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
13. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis 2013;72:627-8.
14. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
15. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
16. Ravelli A, Merni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604.
17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
18. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2004; 50:1761-9.
19. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with long-term glucocorticoids. J Rheumatol 2002;29:1296-300.
20. Arlet JB, Hermine O, Darnige L, Ostland V, Westerman M, Badoual C, et al. Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 2010;126:e1608-12.
21. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.
22. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011;38:764-8.
23. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012;58:287-94.